Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Oct 14, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's sNDA for rufinamide and granted it priority review designation as an adjunctive treatment of...
-
Oct 14, 2014
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its in-house developed agent lenvatinib mesylate (lenvatinib)...
Oct 13, 2014Recognizing unique patient needs on Metastatic Breast Cancer Awareness Day, mbcInfoCenter.com offers important metastatic breast cancer resources in one convenient placeWoodcliff Lake, NJ, October 13, 2014 / PR Newswire / — Understanding the burden of metastatic breast cancer (MBC), and the toll it takes on patients and their loved ones, Eisai Inc....
-
Oct 13, 2014
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American...
-
Oct 13, 2014-- First New Fixed Combination Targeting Two Critical Pathways Involved in CINV --
Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and...
